
Billiontoone Inc (BLLN) Stock Forecast & Price Target
Billiontoone Inc (BLLN) Analyst Ratings
Bulls say
BillionToOne Inc has demonstrated impressive financial performance, with gross margins rising significantly to 53.0% in 2024 from 24.1% due to operational scaling, highlighting effective management of costs alongside revenue growth. The company has reported exceptional year-over-year revenue increases, such as a 102% surge in prenatal test revenue and a staggering 664% growth in oncology revenue, setting the stage for a potential revenue compound annual growth rate (CAGR) exceeding 25% in the reproductive health sector. Furthermore, BillionToOne achieved its first positive net income of $1.5 million, combined with a steady increase in tests per patient, indicating substantial opportunities for future growth and market share acquisition.
Bears say
BillionToOne Inc faces significant challenges that may negatively impact its financial outlook, particularly concerning the protection of its proprietary technology, which could weaken its competitive position. The company is also at risk of reduced revenue due to potential reimbursement decreases under the Medicare program and state Medicaid programs, compounded by increasing denial rates from payers regarding the efficacy of its tests. Moreover, slower-than-anticipated revenue growth from its foundational prenatal testing business and newer oncology tests, alongside potential delays in successful pipeline initiatives, indicates that profitability may be further pressured in the coming periods.
This aggregate rating is based on analysts' research of Billiontoone Inc and is not a guaranteed prediction by Public.com or investment advice.
Billiontoone Inc (BLLN) Analyst Forecast & Price Prediction
Start investing in Billiontoone Inc (BLLN)
Order type
Buy in
Order amount
Est. shares
0 shares